We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

High-Dose Chemotherapy Plus Rituximab Produces High Complete Response Rate

Feb 1, 2001
Volume: 
10
Issue: 
2

HOUSTON—High-dose chemotherapy (HDCT) plus rituximab
(Rituxan) produces responses comparable to HDCT with total body irradiation and
stem cell transplant for aggressive mantle cell lymphoma (MCL), according to
Jorge E. Romaguera, MD, of the University of Texas M. D. Anderson Cancer Center
in Houston, Texas. In a poster presentation, Dr. Romaguera said that HDCT with
rituximab (but without total body irradiation or stem cell transplant) produced
a complete response (CR) rate of 86%.

The failure rate at 9 months median follow-up was comparable to
that observed with stem cell transplant (6% vs 4%) and much better than the 50%
failure rate seen with historical CHOP (cyclophosphamide, doxorubicin, Oncovin
[vincristine], prednisone) controls, he added.

"Patients with mantle cell lymphoma have a poor prognosis.
Anthracycline-containing chemotherapeutic regimens typically provide low
response rates with only 21% complete response, a short median response
duration of 10 months, and dismal survival rates of 2 to 4 years," Dr.
Romaguera said. "A recent CHOP-like regimen of hyperfractionated
cyclophosphamide, doxorubicin, vincristine, and dexamethasone [HCVAD]
alternating with high-dose methotrexate [M] and cytarabine (Ara-C) [A] and
consolidated after four courses with high-dose cyclophosphamide, total body
irradiation, and autologous blood or marrow stem cell transplantation can
achieve 100% CR."

In this earlier study, seven patients did not receive
transplant because of financial reasons, inability to harvest stem cells, or
refusal. Instead, they received up to eight cycles of HCVAD/M-A, which produced
an 86% CR rate with comparable time to progression.

Encouraging Results

"Because of this, we are currently investigating eight
alternating cycles of HCVAD/M-A in previously untreated patients but without
consolidation unless a CR is not achieved after the first six cycles of
treatment," Dr. Romaguera said. "We have included rituximab at 375
mg/m2 given 24 hours before each of the first 6 cycles of therapy." (See
Figure 1.) The dose of cytarabine was limited to 1 g/m2/dose in patients over
age 60 or those having elevated serum creatinine levels.

Patients were restaged at the end of the first two cycles of
therapy. In the case of CR, patients were given four more cycles of therapy. In
the case of partial response (PR), patients were given six more cycles of
therapy. If patients were still in PR after six cycles of therapy, they were
taken off study and offered stem cell transplantation.

Prophylactic granulocyte-colony stimulating factor (G-CSF),
fluconazole (Diflucan), valacyclovir (Valtrex), and levofloxacin (Levaquin)
were given on days 8-17 in cycle 1 and days 5-14 of cycle 2.

Data on 49 evaluable patients were reported, including 37 who
completed six cycles of therapy. Dr. Romaguera reported a CR rate of 86%, an
11% PR rate, and 3% failures. "HCVAD/M-A with rituximab achieves a high
rate of complete remission," he said. "Hematologic toxicity was
severe, but only 8% of patients had grade 3 infections according to NCI
criteria. These results are encouraging and the trial continues to accrue
patients."

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.